Biogen to Acquire Human Immunology Biosciences for $1.15 Billion Upfront, Up to $1.8 Billion Total

May 22, 2024, 12:21 PM

Biogen Inc. has announced an agreement to acquire Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company based in South San Francisco, for $1.15 billion upfront and up to $650 million in potential milestone payments. This acquisition aims to bolster Biogen's late-stage pipeline and expand its immunology portfolio. HI-Bio specializes in targeted therapies for immune-related diseases, including the development of the anti-CD38 antibody Felzartamab and the C5aR1 program. The deal underscores Biogen's strategic shift towards immunology and immune-mediated disorders, diversifying its focus beyond its traditional neuroscience roots. This move continues Biogen's shape-shifting under CEO Chris Viehbacher.